Compare MXE & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXE | ATNM |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 45.2M |
| IPO Year | N/A | N/A |
| Metric | MXE | ATNM |
|---|---|---|
| Price | $13.41 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 5.8K | ★ 133.3K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $8.40 | $1.03 |
| 52 Week High | $11.51 | $2.41 |
| Indicator | MXE | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 75.57 | 36.80 |
| Support Level | $12.95 | $1.27 |
| Resistance Level | $13.52 | $1.38 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 99.28 | 3.70 |
Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.